Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's primary product is the Omnipod platform, which includes the Omnipod 5 automated insulin delivery system. This system features a proprietary algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values via wireless Bluetooth communication. Insulet also offers the Omnipod DASH insulin management system, which uses a Bluetooth-enabled pod controlled by a smartphone-like personal diabetes manager with a color touch screen. Additionally, the company provides pods for Amgen used in the Neulasta Onpro kit, a delivery system to help reduce infection risk after chemotherapy. Insulet sells its products through pharmacy channels and independent distributors.

Insulet Corporation is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol PODD. The company's financial reporting and stock trading are conducted in United States Dollars (USD). As a US-based company, its shares are traded in USD, and all financial figures are reported in this currency.

Insulet Corporation operates in the Healthcare sector and specifically within the Medical Devices industry. This means the company is involved in designing, manufacturing, and marketing medical equipment and devices used for patient care. In Insulet's case, its focus is on insulin delivery systems for diabetes management, which falls under the broader category of medical devices that help monitor and treat chronic conditions.

Insulet Corporation is headquartered in Acton, Massachusetts, United States. The company was incorporated in 2000 and serves customers both in the United States and globally. Its products are sold to end-users through pharmacy channels and independent distributors, indicating a widespread distribution network that reaches patients with insulin-dependent diabetes across multiple regions.

Insulet generates revenue primarily through the sale of its Omnipod platform products, including the Omnipod 5 automated insulin delivery system and the Omnipod DASH insulin management system. These are sold to end-users via pharmacy channels and independent distributors. Additionally, the company provides pods for Amgen's Neulasta Onpro kit, which is used to deliver a drug that helps reduce infection risk after chemotherapy. This partnership represents another revenue stream. By focusing on innovative insulin delivery solutions and leveraging both direct and distributor channels, Insulet captures value from the growing diabetes care market.